tiprankstipranks
Vor Bio reports Q4 EPS (53c), consensus (60c)
The Fly

Vor Bio reports Q4 EPS (53c), consensus (60c)

Cash, cash equivalents and investments were $230.2M as of December 31, 2022, which is projected to fund operations into the first quarter of 2025. "We are encouraged with the initial proof of concept demonstrated in patients treated in our VBP101 study," said Robert Ang, Vor Bio’s president and CEO. "We remain focused on rapid enrollment and plan to share additional clinical data later this year. Our IND for VCAR33ALLO is on-track for submission in the first half of 2023 which, together with trem-cel, has the potential to transform outcomes for patients with blood cancers."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on VOR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles